Q1 2020

Filed May 14, 2020 · 10-Q · 44 days after period end · 0001654954-20-005509

Q1 2020 · 10-Q

Revenue—

Net Income

-$3.32M

N/M vs Q1 2019

EPS Diluted

-$0.29

N/M vs Q1 2019

Operating Income-$3,100,846N/M

Operating Cash Flow-$3,088,367N/M

Same quarter

Metric	Q1 2020	Q1 2019	Q1 2018	Q1 2017
Revenue	—	$0.00	$6.17K	$0.00
Net Income	-$3.32M	-$2.75M	-$2.83M	-$741.62K
EPS Diluted	-$0.29	-$0.37	-$0.72	-$1.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR